1. Home
  2. EFC vs AUPH Comparison

EFC vs AUPH Comparison

Compare EFC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EFC

Ellington Financial Inc.

HOLD

Current Price

$13.22

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.46

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EFC
AUPH
Founded
2007
1993
Country
United States
Canada
Employees
500
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
EFC
AUPH
Price
$13.22
$15.46
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
$14.55
$17.25
AVG Volume (30 Days)
1.2M
980.7K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
11.70%
N/A
EPS Growth
N/A
5075.00
EPS
N/A
2.07
Revenue
N/A
$283,055,000.00
Revenue This Year
N/A
$17.54
Revenue Next Year
$43.05
$15.74
P/E Ratio
$9.50
$7.76
Revenue Growth
N/A
20.38
52 Week Low
$11.28
$7.29
52 Week High
$14.12
$16.88

Technical Indicators

Market Signals
Indicator
EFC
AUPH
Relative Strength Index (RSI) 68.12 46.81
Support Level $12.75 $14.56
Resistance Level $14.00 $16.32
Average True Range (ATR) 0.19 0.52
MACD 0.06 -0.08
Stochastic Oscillator 84.46 9.52

Price Performance

Historical Comparison
EFC
AUPH

About EFC Ellington Financial Inc.

Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. It acquires reverse mortgage loans both through its origination activities and through secondary market purchases.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: